Priority Date: 06.10.11 (US 201161543936P)

USE OF IGF-1 IN THE MODULATION OF TREG CELL ACTIVITY AND THE TREATMENT AND PREVENTION OF AUTOIMMUNE DISORDERS OR DISEASES

  • Application ID: EP12775205
  • Status: APPLICATION DEEMED TO BE WITHDRAWN

Attorney

operating since 1992
Headquarter in Munich and 1 office
active in Legal Services and IP Consulting

Specialization

This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). Zwicker Schnappauf & Partner Patentanwälte PartG mbB (ZSP) is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 226 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 06.10.2011 - Priority Date (US 201161543936P)
  • 11.04.2013 - Publication A2 (WO2013050529)
  • 13.08.2014 - Publication A2 (EP2763692)